When Lianjiu Su and Arjun Deb peered into kidney tissue damaged by toxins, they didn’t just see cells struggling to survive—they saw a hidden signal jamming the body’s natural repair system. At UCLA’s Broad Center of Regenerative Medicine, their team discovered that after injury, the kidney produces a protein called ENPP1 that throws cellular metabolism into chaos, blocking healing and accelerating scar formation. But when they administered a lab-engineered antibody, AD-NP1, to mice with acute kidney damage, something remarkable happened: within just seven days, kidney function improved, cell regeneration surged, and scarring dropped significantly. This isn’t just a second act for a promising drug—it’s a new chapter in how we might treat organ damage across the body.
The discovery, published in Cell Stem Cell, reveals that ENPP1, once thought to be a bystander, is actually a central disruptor of tissue repair. In mice genetically unable to produce ENPP1, levels of serum creatinine, BUN, and cystatin C—key markers of kidney dysfunction—plummeted after four weeks compared to control mice, signaling robust recovery. Even more compelling, when AD-NP1 was given to normal mice with chemically induced kidney injury, their healing mirrored that of the ENPP1-deficient mice. The same protein that impairs heart recovery after a heart attack, the team confirmed, also sabotages the kidney’s ability to bounce back.
What makes this breakthrough especially urgent is its human relevance. Examining biopsies from patients with chronic kidney disease, the researchers found ENPP1 was markedly overexpressed compared to healthy tissue—suggesting the same roadblock exists in people. With over 850 million people worldwide affected by kidney disease, and no therapies that directly enhance regeneration, a drug that could unlock the body’s latent healing power would be transformative. AD-NP1, a monoclonal antibody designed to bind and neutralize human ENPP1 with high specificity, is now entering FDA-approved Phase 1 clinical trials, marking a critical step toward testing its potential in humans.
For Arjun Deb, this is the culmination of years of work tracing how metabolic signals after injury shape recovery. “We found that the same mechanisms we observed in the heart were also applicable in the kidney,” he said. “After injury, healthy cells around the damaged area were trying to proliferate, but the damaged area was sending metabolic signals that prevented the kidney from regenerating and repairing effectively.” Now, with a targeted therapy that silences that signal, the path to organ regeneration is no longer theoretical—it’s within reach. As trials begin, the hope is that one day, a single antibody could help both heart and kidney patients heal from within.